Tecartus
Sep 02, 2024
CAR T-Cell Therapies in Non-Hodgkin’s Lymphoma Treatment: A Revolutionary Approach
CAR-T cells offer a lasting benefit through a single treatment, sparing patients with high-risk conditions from the toxicity associated with salvage chemotherapy and autologous transplants. These approvals have changed the standard of care for patients who are either resistant to initial treatment or experience ear...
Read More...
Sep 13, 2022
Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial
Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
